RB Activity Alters Checkpoint Response and Chemosensitivity in Lung Cancer Lines

Journal of Surgical Research

Volumn 142, Issue 2, 2007, Pages 364-372

  Reed, Michael F ^a,b   Zagorski, William A ^a   Knudsen, Erik S ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

cell cycle; chemotherapy; lung cancer; retinoblastoma

Indexed keywords

ADENOVIRUS VECTOR; CISPLATIN; CYCLIN A; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; FLUOROURACIL; RETINOBLASTOMA PROTEIN; THYMIDYLATE SYNTHASE;

ARTICLE; CELL CYCLE ARREST; CELL VIABILITY; CHEMOSENSITIVITY; COLORIMETRY; DRUG SENSITIVITY; FLOW CYTOMETRY; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL;

ADENOVIRIDAE; ANTINEOPLASTIC AGENTS; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; E2F TRANSCRIPTION FACTORS; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, CDC; GENETIC VECTORS; HUMANS; KIDNEY; LUNG NEOPLASMS; RETINOBLASTOMA PROTEIN;

EID: 34548692307     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2007.03.038     Document Type: Article

References (39)

1. Carney D.N. Lung cancer-time to move on from chemotherapy. N Engl J Med 346 (2002) 126
2. Jemal A., Thomas A., Murray T., et al. Cancer Statistics, 2002. CA Cancer J Clin 52 (2002) 23
3. Meyerson M., Franklin W.A., and Kelley M.J. Molecular classification and molecular genetics of human lung cancers. Semin Oncol 31 (2004) 4
4. Cagle P.T., el-Naggar A.K., Xu H.J., et al. Differential retinoblastoma protein expression in neuroendocrine tumors of the lung. Potential diagnostic implications. Am J Pathol 150 (1997) 393
5. Dosaka-Akita H., Hu S.X., Fujino M., et al. Altered retinoblastoma protein expression in nonsmall cell lung cancer: Its synergistic effects with altered ras and p53 protein status on prognosis. Cancer 79 (1997) 1329
6. Zochbauer-Muller S., Fong K.M., Virmani A.K., et al. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 61 (2001) 249
7. Marchetti A., Buttitta F., Pellegrini S., et al. Alterations of P16 (MTS1) in node-positive non-small cell lung carcinomas. J Pathol 181 (1997) 178
8. Shapiro G.I., Park J.E., Edwards C.D., et al. Multiple mechanisms of p16INK4A inactivation in non-small cell lung cancer cell lines. Cancer Res 55 (1995) 6200
9. Harbour J.W., and Dean D.C. RB function in cell-cycle regulation and apoptosis. Nat Cell Biol 2 (2000) E65
10. Wang J.Y., Knudsen E.S., and Welch P.J. The retinoblastoma tumor suppressor protein. Adv Cancer Res 64 (1994) 25
11. Zhang H.S., Postigo A.A., and Dean D.C. Active transcriptional repression by the Rb-E2F complex mediates G1 arrest triggered by p16INK4a, TGFβ, and contact inhibition. Cell 97 (1999) 53
12. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev 12 (1998) 2245
13. Strobeck M.W., Fribourg A.F., Puga A., et al. Restoration of retinoblastoma mediated signaling to Cdk2 results in cell cycle arrest. Oncogene 19 (2000) 1857
14. Zhang H.S., Gavin M., Dahiya A., et al. Exit from G1 and S phase of the cell cycle is regulated by repressor complexes containing HDAC-Rb-hSWI/SNF and Rb-hSWI/SNF. Cell 101 (2000) 79
15. Ewen M.E., Sluss H.K., Sherr C.J., et al. Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell 73 (1993) 487
16. Kato J., Matsushime H., Hiebert S.W., et al. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev 7 (1993) 331
17. Harbour J.W., Luo R.X., Dei Santi A., et al. CDK phosphorylation triggers sequential intramolecular interactions that progressively block RB functions as cells move through G1. Cell 98 (1999) 859
18. Hartwell L.H., and Weinert T.A. Checkpoints: Controls that ensure the order of cell cycle events. Science 246 (1989) 629
19. Nyberg K.A., Michelson R.J., Putnam C.W., et al. Toward maintaining the genome: DNA damage and replication checkpoints. Annu Rev Genet 36 (2002) 617
20. Bartkova J., Lukas J., and Bartek J. Aberrations of the G1- and G1/S-regulating genes in human cancer. Prog Cell Cycle Res 3 (1997) 211
21. Flatt P.M., and Pietenpol J.A. Mechanisms of cell-cycle checkpoints: At the crossroads of carcinogenesis and drug discovery. Drug Metab Rev 32 (2000) 283
22. Harrington E.A., Bruce J.L., Harlow E., et al. pRB plays an essential role in cell cycle arrest induced by DNA damage. Proc Natl Acad Sci USA 95 (1998) 11945
23. Knudsen K.E., Booth D., Naderi S., et al. RB-dependent S-phase response to DNA damage. Mol Cell Biol 20 (2000) 7751
24. Markey M.P., Angus S.P., Strobeck M.W., et al. Unbiased analysis of RB-mediated transcriptional repression identifies novel targets and distinctions from E2F Action. Cancer Res 62 (2002) 6587
25. Li W., Fan J., Hochhauser D., et al. Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines. Proc Natl Acad Sci USA 92 (1995) 10436
26. Bosco E.E., Mayhew C.N., Hennigan R.F., et al. RB signaling prevents replication-dependent DNA double-strand breaks following genotoxic insult. Nucleic Acids Res 32 (2004) 25
27. Mayhew C.N., Perkin L.M., Zhang X., et al. Discrete signaling pathways participate in RB-dependent responses to chemotherapeutic agents. Oncogene 23 (2004) 4107
28. Knudsen E.S., and Wang J.Y. Differential regulation of retinoblastoma protein function by specific CDK phosphorylation sites. J Biol Chem 271 (1996) 8313
29. Knudsen E.S., Buckmaster C., Chen T.T., et al. Inhibition of DNA synthesis by RB: Effects on G1/S transition and S-phase progression. Genes Dev 12 (1998) 2278
30. Shimizu E., Coxon A., Otterson G.A., et al. RB protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma. Oncogene 9 (1994) 2441
31. Sherr C.J., and McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2 (2002) 103
32. The International Adjuvant Lung Cancer Trial Collaborative Group: cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350 (2004) 351
33. Winton T., Livingston R., Johnson D., et al. Vinorelbine plus cisplatin versus observation in resected non-small-cell lung cancer. N Engl J Med 352 (2005) 2589
34. Almasan A., Yin Y., Kelly R.E., et al. Deficiency of retinoblastoma protein leads to inappropriate S-phase entry, activation of E2F-responsive genes, and apoptosis. Proc Natl Acad Sci USA 92 (1995) 5436
35. Mayhew C.N., Bosco E.E., Solomon D.A., et al. Analysis of RB action in DNA damage checkpoint response. Methods Mol Biol 281 (2004) 3
36. Bosco E.E., and Knudsen E.S. Differential role of RB in response to UV and IR damage. Nucleic Acids Res 33 (2005) 1581
37. Shackney S.E., and Shankey T.V. Common patterns of genetic evolution in human solid tumors. Cytometry 29 (1997) 1
38. Schnier J.B., Nishi K., Goodrich D.W., et al. G1 arrest and down-regulation of cyclin E/cyclin-dependent kinase 2 by the protein kinase inhibitor staurosporine are dependent on the retinoblastoma protein in the bladder carcinoma cell line 5637. Proc Natl Acad Sci USA 93 (1996) 5941
39. Shinohara H., Zhou J., Yoshikawa K., et al. Retinoblastoma protein-initiated cellular growth arrest overcomes the ability of cotransfected wild-type p53 to induce apoptosis. Br J Cancer 83 (2000) 1039